Clusterin is overexpressed in a variety of cancers including breast (Ranney et al., 2007; Yom et al., 2009), ovarian (Xie D. et al., 2005; Wei et al., 2009), and prostate cancer (July et al., 2002), where it promotes tumorigenesis and contributes to chemoresistance (Cao et al., 2005; Flanagan et al., 2010; Kususda et al., 2012; Tang et al., 2012; Xiu et al., 2013). Here, CLU is linked to Familial prostate cancer.